Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ace Convergence Acquisition Corp. was a special purpose acquisition company (SPAC), commonly known as a "blank check company," incorporated in 2020 and based in Wilmington, Delaware. Its sole purpose was to identify and merge with or acquire a business within the IT infrastructure software and semiconductor sectors. The company had no independent business operations, revenue, or product pipeline; it was a vehicle for effecting a business combination, not a therapeutic or diagnostic enterprise. It completed its intended business combination with Tempo Automation in late 2022 and ceased to trade on NASDAQ as an independent entity. The stock is now traded on OTC Markets (ACEVU), reflecting its inactive status. It did not target any diseases, biological pathways, or therapeutic modalities; it had no pipeline, clinical programs, or platform technologies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ace Convergence Acquisition Corp..